Research programme: glioma therapeutics - Stemergie Biotechnology/Swiss Federal Institute of Technology Zurich
Latest Information Update: 10 Aug 2016
At a glance
- Originator Stemergie Biotechnology; Swiss Federal Institute of Technology Zurich
- Class Antineoplastics; Small molecules
- Mechanism of Action Electron transport complex I inhibitors; Electron transport complex III inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Glioma
Most Recent Events
- 10 Aug 2016 Early research in Glioma in Switzerland (unspecified route)